Dominika J. Burek

Dominika J. Burek

Auto-generated profile, based on publicly available information

Dominika J. Burek

Basic Neuroscience Division, McLean Hospital, Belmont, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2016 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
EHElizabeth Heller
Elizabeth Heller
PHPeter J Hamilton
Peter J Hamilton
DBDominika D. Burek
Dominika D. Burek
SLSonia I. Lombroso
Sonia I. Lombroso
CPCatherine J. Peña
Catherine J. Peña
ENEric J Nestler
Eric J Nestler
Recent studies have implicated epigenetic remodeling in brain reward regions following psychostimulant or stress exposure. It has only recently become possible to target a given type of epigenetic remodeling to a single gene of interest, and to probe the functional relevance of such regulation to neuropsychiatric disease. We sought to examine the role of histone modifications at the murineCdk5(cyclin-dependent kinase 5) locus, given growing evidence ofCdk5expression in nucleus accumbens (NAc) influencing reward-related behaviors. Viral-mediated delivery of engineered zinc finger proteins (ZFP) targeted histone H3 lysine 9/14 acetylation (H3K9/14ac), a transcriptionally active mark, or histone H3 lysine 9 dimethylation (H3K9me2), which is associated with transcriptional repression, specifically to theCdk5locus in NAcin vivo. We found thatCdk5-ZFP transcription factors are sufficient to bidirectionally regulateCdk5gene expression via enrichment of their respective histone modifications. We examined the behavioral consequences of this epigenetic remodeling and found thatCdk5-targeted H3K9/14ac increased cocaine-induced locomotor behavior, as well as resilience to social stress. Conversely,Cdk5-targeted H3K9me2 attenuated both cocaine-induced locomotor behavior and conditioned place preference, but had no effect on stress-induced social avoidance behavior. The current study provides evidence for the causal role ofCdk5epigenetic remodeling in NAc inCdk5gene expression and in the control of reward and stress responses. Moreover, these data are especially compelling given that previous work demonstrated opposite behavioral phenotypes compared with those reported here uponCdk5overexpression or knockdown, demonstrating the importance of targeted epigenetic remodeling tools for studying more subtle molecular changes that contribute to neuropsychiatric disease.SIGNIFICANCE STATEMENTAddiction and depression are highly heritable diseases, yet it has been difficult to identify gene sequence variations that underlie this heritability. Gene regulation via epigenetic remodeling is an additional mechanism contributing to the neurobiological basis of drug and stress exposure. In particular, epigenetic regulation of theCdk5gene alters responses to cocaine and stress in mouse and rat models. In this study, we used a novel technology, zinc-finger engineered transcription factors, to remodel histone proteins specifically at theCdk5gene. We found that this is sufficient to regulate the expression ofCdk5and results in altered behavioral responses to cocaine and social stress. These data provide compelling evidence of the significance of epigenetic regulation in the neurobiological basis of reward- and stress-related neuropsychiatric disease.

3 December 2014 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
RGRoss C. Gruber
Ross C. Gruber
ARAlex K. Ray
Alex K. Ray
CJChristopher T. Johndrow
Christopher T. Johndrow
HGHillary Guzik
Hillary Guzik
DBDominika Burek
Dominika Burek
BSBridget Shafit-Zagardo
Bridget Shafit-Zagardo
Growth arrest-specific protein 6 (GAS6) is a soluble agonist of the TYRO3, AXL, MERTK (TAM) family of receptor tyrosine kinases identified to have anti-inflammatory, neuroprotective, and promyelinating properties. During experimental autoimmune encephalomyelitis (EAE), wild-type (WT) mice demonstrate a significant induction ofGas6,Axl, andMertkbut notPros1orTyro3mRNA. We tested the hypothesis that intracerebroventricular delivery of GAS6 directly into the CNS of WT mice during myelin oligodendrocyte glycoprotein (MOG)-induced EAE would improve the clinical course of disease relative to artificial CSF (ACSF)-treated mice. GAS6 did not delay disease onset, but significantly reduced the clinical scores during peak and chronic EAE. Mice receiving GAS6 for 28 d had preserved SMI31+neurofilament immunoreactivity, significantly fewer SMI32+axonal swellings and spheroids and less demyelination relative to ACSF-treated mice. Alternate-day subcutaneous IFNβ injection did not enhance GAS6 treatment effectiveness.Gas6−/−mice sensitized with MOG35-55peptide exhibit higher clinical scores during late peak to early chronic disease, with significantly increased SMI32+axonal swellings and Iba1+microglia/macrophages, enhanced expression of several proinflammatory mRNA molecules, and decreased expression of early oligodendrocyte maturation markers relative to WT mouse spinal cords with scores for 8 consecutive days. During acute EAE, flow cytometry showed significantly more macrophages but not T-cell infiltrates inGas6−/−spinal cords than WT spinal cords. Our data are consistent with GAS6 being protective during EAE by dampening the inflammatory response, thereby preserving axonal integrity and myelination.

1 December 2017 in Biological Psychiatry
Verified
Journal Article
Closed access
OEOlivia Engmann
Olivia Engmann
BLBenoit Labonté
Benoit Labonté
AMAmanda Mitchell
Amanda Mitchell
PBPavel Bashtrykov
Pavel Bashtrykov
ECErin S. Calipari
Erin S. Calipari
ENEric J Nestler
Eric J Nestler

22 June 2025 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
DBDominika J. Burek
Dominika J. Burek
KIKhairunisa Mohamad Ibrahim
Khairunisa Mohamad Ibrahim
AHAndrew G. Hall
Andrew G. Hall
ASAshish Sharma
Ashish Sharma
JCJessica A. Cucinello-Ragland
Jessica A. Cucinello-Ragland
WCWilliam A. Carlezon
William A. Carlezon
Pain syndromes include physical, sensory, emotional, and cognitive symptoms such as disability, negative affect, feelings of stress, and fatigue. Experimental induction of long-term inflammatory pain in rodents by hindpaw injection of complete Freund’s adjuvant (CFA) produces anhedonia and dysregulated naturalistic behaviors, similar to the effects of unregulated stress. We examined whether these similarities extend to changes in sleep and rhythms, such as those induced by chronic social defeat stress, using actigraphy and wireless EEG in mice. Comparisons were made between groups that received injections at the onset of the light or dark phase. We found that CFA-induced inflammatory pain alters sleep architecture in both sexes; most notably, it increased sleep duration in the dark phase—when mice are normally more likely to be awake—while also increasing sleep bout length and reducing wake bout length. In contrast, during the light phase, it decreased sleep bout length, indicating fragmentation. Similarly, CFA-induced increases in REM and SWS duration and bouts were largest during the dark phase. Dark-phase effects were remarkably consistent regardless of whether the mice had been injected at darkness onset or 12 h earlier, whereas light-phase effects were more dependent on time since injection. Injections also produced non-specific alterations in circadian rhythmicity. Our findings indicate that inflammatory pain prominently increases sleep during normally active phases as well as transitions between sleep and wakefulness throughout the day. These effects align with clinical observations and establish a basis for mechanistic studies and use of these procedures to better predict outcomes in humans.

6 October 2025 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
AHAndrew G. Hall
Andrew G. Hall
DBDominika J. Burek
Dominika J. Burek
EHErin E. Hisey
Erin E. Hisey
LSLauren T. Seabrook
Lauren T. Seabrook
EFEmma L. Fritsch
Emma L. Fritsch
WJWilliam A. Carlezon Jr
William A. Carlezon Jr
Early-life stress (ELS) can produce long-lasting effects that increase the risk for mood and anxiety disorders. Transdiagnostic symptoms include anhedonia (reduced reward sensitivity) and sleep disruption, both of which are quantifiable via objective endpoints that can be utilized across species. Here we used a mouse model for ELS—exposure to juvenile chronic social defeat stress (jCSDS)—together with translationally-applicable endpoints to examine correspondence between sleep patterns and anhedonia. These initial studies focused on males, which typically show robust defeat-induced anhedonia phenotypes. Exposure to jCSDS produced reductions in open-field social behavior, an endpoint commonly used in mice to quantify stress effects, during adulthood. Mice were then implanted with wireless transmitters that enable continuous EEG-derived analysis of sleep architecture. Following assessment of baseline sleep patterns, mice were tested in a rodent version of the Probabilistic Reward Task (PRT), a procedure used to quantify reward responsiveness in humans, during the light phase of their diurnal cycle. These studies revealed significant associations between baseline sleep architecture and anhedonic phenotypes in jCSDS-exposed mice: higher anhedonia correlated with less time awake and more time in slow wave sleep (SWS) during the light phase, and more time awake and less time in rapid eye movement (REM) sleep and SWS during the dark (active) phase. Our findings suggest that sleep patterns represent a biomarker that can predict stress-susceptible (higher anhedonia) and resilient (lower anhedonia) phenotypes. This work enhances our understanding of relationships between sleep and anhedonia, and may provide a basis for precision approaches to treat ELS-induced pathophysiology.